-
Finerenone improves long-term survival benefits in patients with worsening heart failure, finds study
18 Oct 2024 02:47 GMT
… increase event-free survival in heart failure (HF) patients with … age, the individuals with heart failure who have a little … the expected long-term therapeutic effects of finerenone in … Term Benefits of Finerenone in Heart Failure. In JAMA Cardiology. …
-
Speakers highlight 2024 regulatory moves in hypertension, lipid, diabetes therapies
17 Oct 2024 22:08 GMT
… management, breakthrough lipid therapies and rejected diabetes therapeutics.
There have been … furosemide injection for patients with heart failure. Read more
FDA approves … The FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuticals’ …
-
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
17 Oct 2024 20:30 GMT
… of serious complications, such as heart failure and ventricular arrhythmias, highlighting … European Commission. About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage … and deliver potentially curative therapies that address the underlying drivers …
-
Diastolic Heart Failure Drug Market by Technology, Product, Application, and Geography - Forecast and Analysis 2024-2032
17 Oct 2024 10:58 GMT
… landscape of the diastolic heart failure drug market, highlighting key … ( Brazil)
Introduction:
Diastolic heart failure, or heart failure with preserved ejection fraction ( … obesity, and diabetes.
Emerging therapies and lifestyle modifications, such …
-
New protein shows potential for treating systolic heart failure
17 Oct 2024 01:21 GMT
… could be a new therapeutic approach to systolic heart failure.
In recent decades … actually worsen patient outcomes.
Systolic heart failure results from a vicious cycle … may be a new therapeutic to treat systolic heart failure by simultaneously addressing …
-
Enhancing Outcomes in Outpatient Parenteral Antimicrobial Therapy
17 Oct 2024 13:15 GMT
… kidney disease (36.5%), and heart failure (28.9%). The most common … . Evaluation of Outpatient Parenteral Antimicrobial Therapy Practices within a Large Healthcare …
-
AskBio Announces 11 Presentations at the European Society of Gene and Cell Therapy 31st Annual Meeting 2024
17 Oct 2024 12:00 GMT
… , an investigational gene therapy in congestive heart failure, and the initiation … pipeline that includes investigational therapeutics for congestive heart failure, Huntington’s disease … Malik A, et al. Congestive Heart Failure. In: StatPearls. Treasure Island …
-
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
17 Oct 2024 11:01 GMT
… April 2024. In 2021, Travere Therapeutics granted CSL Vifor exclusive commercialization … New Zealand. About Travere Therapeutics At Travere Therapeutics, we are in rare … been evaluated in patients with heart failure. If clinically significant fluid retention …
-
NYU Langone researchers address the challenges of heart failure in cancer patients
16 Oct 2024 04:32 GMT
… imaging protocols during cancer therapies to prevent heart-related … antibodies, very few cancer therapeutics have standardized cardiac imaging surveillance … and Heart Failure: AL Amyloidosis for the Heart Failure Clinician" and "Heart Failure …
-
An Overview of SGLT2 Inhibitors in Heart Failure With Preserved Ejection Faction
15 Oct 2024 20:41 GMT
… prevalence of HFpEF compared to heart failure with reserved ejection fraction (HFrEF … -transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021; … The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a …